A new drug combo for advanced breast cancer after standard treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug combination for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after standard treatments like CDK4/6 inhibitors and hormone therapy. It aims to see if the combination can help when other options have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- Your cancer must be HR-positive and HER2-negative, as confirmed by a biopsy.
- Your cancer must have gotten worse after you received treatments like CDK4/6 inhibitors and hormone therapy.
- You must have at least one tumor that can be measured on a CT scan or MRI and has not been treated with radiation.
- Your blood counts, liver and kidney function must be within certain safe limits.
- You must be willing to use effective birth control during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug (SHR-A1811) combined with fulvestrant, with or without another drug (HS-10352), for people with advanced breast cancer that has not been treated before. The goal is to see if these combinations can help control the cancer.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.